Martin Wehling, MD, is full Professor of Clinical Pharmacology at the University of Heidelberg. He is also board certified internist (cardiologist) and has longstanding experiences in basic science (cell physiology, steroid pharmacology, nongenomic steroid actions), clinical trials (translating basic science into human studies) and clinical medicine (invasive cardiology, endocrinology). In 2004, he was appointed by AstraZeneca as Director of discovery (=translational) medicine. Returning to academia in 2007, he promotes translational medicine by aligning academic and private activities. Main tools are connecting distant players in the translational process, assembling, developing and profiling of biomarkers and developing smart translational plans to promote promising projects. Martin Wehling, MD, is full Professor of Clinical Pharmacology at the University of Heidelberg. He is also board certified internist (cardiologist) and has longstanding experiences in basic science (cell physiology, steroid pharmacology, nongenomic steroid actions), clinical trials (translating basic science into human studies) and clinical medicine (invasive cardiology, endocrinology). In 2004, he was appointed by AstraZeneca as Director of discovery (=translational) medicine. Returning to academia in 2007, he promotes translational medicine by aligning academic and private activities. Main tools are connecting distant players in the translational process, assembling, developing and profiling of biomarkers and developing smart translational plans to promote promising projects.

Medicine